Dr. Iain Chessell is the Head of the Neuroscience effort at MedImmune, leading a cross-functional team dedicated to and advancement of the IMED’s large molecule neuroscience portfolio.

Dr. Chessell joined MedImmune in November 2008 as vice president, Research. In this role, he was responsible for overseeing MedImmune’s preclinical programs, including those targeting pain control (analgesia) and neurodegenerative diseases such as Alzheimer’s disease. In 2010 he was promoted to vice president and head of the Neuroscience Center of Excellence (CoE).

Prior to joining MedImmune, Dr. Chessell was chief executive officer at NeuroDiscovery where he completed a number of Phase 1 and Phase 2 clinical programs, and restructured a parallel revenue business to maximise profitability and efficiency. Previously, Dr. Chessell was worldwide head of pain research for GlaxoSmithKline, where he delivered eight clinical candidates in the period 2004-2007, and was involved in multiple clinical development projects from Phase 1 to Phase 3. He was also responsible for review of potential in-license opportunities, and was chair of the core disease teams for pain and neurodegeneration, as well as serving as chair of the Neurology Centre of Excellence for Drug Discovery (CEDD) management team. Dr. Chessell also managed several high profile academic and industrial collaborations, and is author of more than 80 peer reviewed publications.

Dr. Chessell received his bachelor’s degree in pharmacology from University College London, where he graduated first class with honours. He received his doctoral degree from the Department of Neurochemistry at the Institute of Neurology, London.